• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过片段生长研究设计的 8-烷基噻唑并[5,4-]喹唑啉-9-酮的金属催化 C⁻H 芳基化来开发激酶抑制剂。

Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-]-quinazolin-9-ones Designed by Fragment-Growing Studies.

机构信息

Normandie University, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France.

Institut de Chimie Organique et Analytique (ICOA), Université d'Orléans, UMR CNRS, 7311 BP 6759, 45067 Orléans CEDEX 2, France.

出版信息

Molecules. 2018 Aug 29;23(9):2181. doi: 10.3390/molecules23092181.

DOI:10.3390/molecules23092181
PMID:30158487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6225322/
Abstract

Efficient metal catalyzed C⁻H arylation of 8-alkyl-thiazolo[5,4-]-quinazolin-9-ones was explored for SAR studies. Application of this powerful chemical tool at the last stage of the synthesis of kinase inhibitors allowed the synthesis of arrays of molecules inspired by fragment-growing studies generated by molecular modeling calculations. Among the potentially active compounds designed through this strategy, () exhibits nanomolar IC values against some kinases, and is the best candidate for the development as a DYRK kinase inhibitor.

摘要

探索了高效的金属催化 C⁻H 芳基化 8-烷基噻唑并[5,4-]喹唑啉-9-酮,以进行 SAR 研究。该强大化学工具在激酶抑制剂合成的最后阶段的应用,允许通过分子建模计算生成的片段生长研究的灵感分子进行阵列合成。在所设计的潜在活性化合物中,()对一些激酶表现出纳摩尔的 IC 值,是作为 DYRK 激酶抑制剂开发的最佳候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/40e65162ec0d/molecules-23-02181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/2d5e21fea96f/molecules-23-02181-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/79a4c8a1697d/molecules-23-02181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/97d80e3449a9/molecules-23-02181-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/ee75696839d7/molecules-23-02181-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/f8a645981838/molecules-23-02181-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/32c4a20f0cdd/molecules-23-02181-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/81fc67a9a7b7/molecules-23-02181-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/9dbfabeea501/molecules-23-02181-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/eb341dbbbeb7/molecules-23-02181-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/ea9c14470747/molecules-23-02181-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/d5744ca25a74/molecules-23-02181-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/955a17311fcc/molecules-23-02181-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/40e65162ec0d/molecules-23-02181-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/2d5e21fea96f/molecules-23-02181-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/79a4c8a1697d/molecules-23-02181-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/97d80e3449a9/molecules-23-02181-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/ee75696839d7/molecules-23-02181-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/f8a645981838/molecules-23-02181-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/32c4a20f0cdd/molecules-23-02181-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/81fc67a9a7b7/molecules-23-02181-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/9dbfabeea501/molecules-23-02181-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/eb341dbbbeb7/molecules-23-02181-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/ea9c14470747/molecules-23-02181-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/d5744ca25a74/molecules-23-02181-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/955a17311fcc/molecules-23-02181-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7cb/6225322/40e65162ec0d/molecules-23-02181-g003.jpg

相似文献

1
Development of Kinase Inhibitors via Metal-Catalyzed C⁻H Arylation of 8-Alkyl-thiazolo[5,4-]-quinazolin-9-ones Designed by Fragment-Growing Studies.通过片段生长研究设计的 8-烷基噻唑并[5,4-]喹唑啉-9-酮的金属催化 C⁻H 芳基化来开发激酶抑制剂。
Molecules. 2018 Aug 29;23(9):2181. doi: 10.3390/molecules23092181.
2
Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.噻唑并[5,4-f]喹唑啉类化合物作为DYRK1A抑制剂的设计与合成,第一部分。
Molecules. 2014 Sep 29;19(10):15546-71. doi: 10.3390/molecules191015546.
3
Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases.噻唑并[5,4-f]喹唑啉-9(8H)-酮作为丝氨酸/苏氨酸激酶多靶点导向配体的合成
Molecules. 2016 Apr 30;21(5):578. doi: 10.3390/molecules21050578.
4
Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the Hügershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation.通过许格斯霍夫反应或铜催化的分子内C-S键形成合成生物活性2-(芳基氨基)噻唑并[5,4-f]喹唑啉-9-酮
Molecules. 2016 Jun 18;21(6):794. doi: 10.3390/molecules21060794.
5
Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.吡啶并[4,3-h]和[3,4-g]喹唑啉中的激酶抑制作用:合成、SAR 和分子模拟研究。
Bioorg Med Chem. 2019 May 15;27(10):2083-2089. doi: 10.1016/j.bmc.2019.04.005. Epub 2019 Apr 4.
6
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.新型吡啶并[3,4-g]喹唑啉衍生物作为 CLK1 和 DYRK1A 的抑制剂:合成、生物评价及结合模式分析。
Eur J Med Chem. 2019 Mar 15;166:304-317. doi: 10.1016/j.ejmech.2019.01.052. Epub 2019 Jan 26.
7
Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.噻唑并[5,4-f]喹唑啉类化合物作为DYRK1A抑制剂的设计与合成,第二部分。
Molecules. 2014 Sep 26;19(10):15411-39. doi: 10.3390/molecules191015411.
8
Synthesis, biological evaluation and molecular modelling studies of 4-anilinoquinazoline derivatives as protein kinase inhibitors.4-苯胺基喹唑啉衍生物作为蛋白激酶抑制剂的合成、生物学评价及分子模拟研究
Bioorg Med Chem. 2014 Mar 15;22(6):1909-15. doi: 10.1016/j.bmc.2014.01.044. Epub 2014 Jan 31.
9
Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors.咪唑并[1,2-a]吡啶衍生物作为蛋白激酶抑制剂的合成、生物学评价及分子模拟研究
Eur J Med Chem. 2016 Nov 10;123:105-114. doi: 10.1016/j.ejmech.2016.07.040. Epub 2016 Jul 21.
10
Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.发现吡啶并[3,4-g]喹唑啉衍生物作为 CMGC 家族蛋白激酶抑制剂:设计、合成、抑制活性和 X 射线共晶结构。
Eur J Med Chem. 2016 Aug 8;118:170-7. doi: 10.1016/j.ejmech.2016.04.004. Epub 2016 Apr 5.

引用本文的文献

1
29th Annual GP2A Medicinal Chemistry Conference.第29届年度GP2A药物化学会议。
Pharmaceuticals (Basel). 2021 Dec 7;14(12):1278. doi: 10.3390/ph14121278.
2
Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-]quinazolin-9(8)-one, a Promising Inhibitor of DYRK1A.8-环丙基-2-(吡啶-3-基)噻唑并[5,4-]喹唑啉-9(8)-酮的生物学特性,一种有前景的双重特异性酪氨酸激酶1A(DYRK1A)抑制剂
Pharmaceuticals (Basel). 2019 Dec 17;12(4):185. doi: 10.3390/ph12040185.
3
Alkaloid Enantiomers from the Roots of .从 的根部提取的生物碱对映异构体。

本文引用的文献

1
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.双重特异性酪氨酸磷酸化调节激酶 1A(DYRK1A)抑制剂作为潜在的治疗药物。
J Med Chem. 2018 Nov 21;61(22):9791-9810. doi: 10.1021/acs.jmedchem.8b00185. Epub 2018 Jul 20.
2
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials.PKIDB:一个经过精心策划、注释和更新的临床试验中蛋白激酶抑制剂数据库。
Molecules. 2018 Apr 15;23(4):908. doi: 10.3390/molecules23040908.
3
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Molecules. 2019 Aug 29;24(17):3140. doi: 10.3390/molecules24173140.
双特异性酪氨酸磷酸化调节激酶1A(DYRK1A)抑制剂:近期专利文献综述
Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. doi: 10.1080/13543776.2017.1360285. Epub 2017 Aug 2.
4
An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.9-苯胺基噻唑并[5,4-f]喹唑啉-2-甲脒酯(EHT 1610和EHT 5372)的一种异常结合模式赋予了对双特异性酪氨酸磷酸化调节激酶的高选择性。
J Med Chem. 2016 Nov 23;59(22):10315-10321. doi: 10.1021/acs.jmedchem.6b01083. Epub 2016 Nov 2.
5
Synthesis of Bioactive 2-(Arylamino)thiazolo[5,4-f]-quinazolin-9-ones via the Hügershoff Reaction or Cu- Catalyzed Intramolecular C-S Bond Formation.通过许格斯霍夫反应或铜催化的分子内C-S键形成合成生物活性2-(芳基氨基)噻唑并[5,4-f]喹唑啉-9-酮
Molecules. 2016 Jun 18;21(6):794. doi: 10.3390/molecules21060794.
6
Pd-Catalyzed and Copper Assisted Regioselective Sequential C2 and C7 Arylation of Thiazolo[5,4-f]quinazolin-9(8H)-one with Aryl Halides.钯催化和铜辅助的噻唑并[5,4-f]喹唑啉-9(8H)-酮与芳基卤化物的区域选择性顺序 C2 和 C7 芳基化。
Org Lett. 2016 Jul 1;18(13):3282-5. doi: 10.1021/acs.orglett.6b01552. Epub 2016 Jun 17.
7
Synthesis of Thiazolo[5,4-f]quinazolin-9(8H)-ones as Multi-Target Directed Ligands of Ser/Thr Kinases.噻唑并[5,4-f]喹唑啉-9(8H)-酮作为丝氨酸/苏氨酸激酶多靶点导向配体的合成
Molecules. 2016 Apr 30;21(5):578. doi: 10.3390/molecules21050578.
8
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.小分子激酶抑制剂:FDA 批准药物分析。
Drug Discov Today. 2016 Jan;21(1):5-10. doi: 10.1016/j.drudis.2015.07.008. Epub 2015 Jul 23.
9
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.DYRK1A 在神经退行性疾病和癌症中的作用:分子基础和临床意义。
Pharmacol Ther. 2015 Jul;151:87-98. doi: 10.1016/j.pharmthera.2015.03.004. Epub 2015 Mar 17.
10
A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.一种用于治疗阿尔茨海默病的新型DYRK1A(双重特异性酪氨酸磷酸化调节激酶1A)抑制剂:体外对Tau蛋白和淀粉样病变的影响
J Neurochem. 2015 May;133(3):440-51. doi: 10.1111/jnc.13018. Epub 2015 Jan 26.